Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_assertion type Assertion NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_head.
- NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_assertion description "[Using pancreatic cancer microarrays and immunohistochemistry, we determined that 6% (4 of 46 and 5 of 100 in two independent panels) of pancreatic adenocarcinomas overexpress cyclin E. We identified two potential mechanisms for this overexpression including the amplification/gain of CCNE1 gene copies in the Panc-1 and Su86.86 cell lines and a novel somatic homozygous mutation (H460R, in one of 11 pancreatic cancer xenografts having allelic loss) in FBXW7, which was accompanied by cyclin E overexpression by immunohistochemistry.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_provenance.
- NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_assertion evidence source_evidence_literature NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_provenance.
- NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_assertion SIO_000772 14507635 NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_provenance.
- NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_assertion wasDerivedFrom befree-20140225 NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_provenance.
- NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_assertion wasGeneratedBy ECO_0000203 NP780227.RA32gQJ4vZo0r1BOlQWX1W0IAiqorUPGs2o7pZY0uWf6s130_provenance.